Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Incyte ditches phase 1-stage JAK inhibitor to pursue next-gen options
(4h)
Altimmune’s next-gen GLP-1 curbs heavy drinking in ‘unequivocal’ ph. 2 alcohol use disorder win
(4h)
GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyard
(5h)
Atea’s hepatitis C asset matches Gilead’s Epclusa in phase 3 trial
(5h)
Acrosian debuts as AI-focused biometrics CRO
(6h)
Guardant Health taps Patrick Dempsey for emotional colorectal cancer awareness video
(6h)
GSK partner Hansoh reports another phase 3 win for priority ADC
(7h)
Boston Scientific unveils major restructuring, plots job cuts amid savings drive
(12h)
‘This could be a large market’: Novo Holdings-backed Claris secures $118M for corneal disease drug
(21h)
RA Capital launches rare disease company Oak Hill Bio onto Nasdaq via SPAC
(1d)
BioPharma Dive
GSK prepares for patent cliff with $2.5B cost-cutting plan
(3h)
The FDA was all in on AI. Will that change?
(7h)
An eye drug biotech banks $118M and stocks its executive suite
(7h)
MapLight dives despite positive data for schizophrenia drug
(1d)
Argenx to acquire Forte in $2.2B deal for ‘differentiated’ immune drug
(1d)
FDA scientists question Capricor data; Legend CEO steps down
(1d)
Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO
(1d)
From confidence to capital: Positioning biotech for the next growth cycle
(1d)
Sanofi halts development of troubled immune drug in eczema
(4d)
Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma
(4d)
Endpoints News
J&J proposes $5.5B talc settlement
(35m)
FDA offers updated guidance for generics of weight loss blockbusters
(1h)
Oak Hill Bio merges with RA Capital SPAC; InnoCare's TYK2 drug hits in Phase 3
(3h)
FDA staff say Replimune's melanoma trial failed to prove RP1 works
(4h)
The future of gray-market peptides
(4h)
Alnylam's stock is down 30% despite a booming biotech market. Here's why.
(5h)
Mirae raises $5.4M to turn patient texts into data for doctors
(5h)
Claris collects $118M to take eye drop into pivotal testing next year
(7h)
GSK to start three-year plan to save cash, takes £1.33B hit on cough trial failure
(7h)
Altimmune’s GLP-1-based shot cuts drinking in patients with alcoholism
(8h)
BioSpace
GSK shares rise as $2.5B cost-cutting plan unveiled
(4h)
FDA says Replimune’s melanoma data package is ‘not interpretable,’ setting up tough adcomm
(5h)
Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study
(6h)
Apnimed eyes up to $160M IPO to prep for sleep apnea drug launch
(7h)
Oak Hill takes SPAC track to Nasdaq with Roche asset in tow
(8h)
As pharma descends on China for deals, BIOSECURE Act raises intellectual property risk
(14h)
FDA disputes Capricor's claims of Phase 3 success for DMD cell therapy
(1d)
MapLight’s schizophrenia pill remains in Cobenfy’s shadow after mixed Phase 2 readout
(1d)
Gossamer regains rights to lung disease asset from Chiesi after Phase 3 fail
(1d)
Sarepta names former AbbVie R&D exec Michael Severino as next CEO
(1d)
STAT News
Visa time limits on foreign Ph.D. students and postdocs will harm U.S. science, experts warn
(2h)
Bracing for another Fauci hearing
(2h)
GSK lays out plans to cut costs, pursue more late-stage drug trials
(4h)
FDA staff reiterate concerns about Replimmune skin cancer treatment
(5h)
We’re reading about FDA views on a Duchenne drug, GSK cost savings, and more
(5h)
Three questions with Whoop’s new CMO
(5h)
Anthony Fauci’s pandemic-era diary entries
(7h)
Preliminary trial results suggest a path to a safer Alzheimer’s treatment
(9h)
CMS evaluates one year of health tech progress, announces eight new pledge categories
(10h)
From ‘lost cause’ to gold rush: Biotechs swarm to cure AATD
(10h)
BioPharma Trend
Seven HealthTech Trends In Europe To Watch
(1mo)
Self-Care Is Not a Product, It’s Critical Infrastructure: Why We Must Work Together to Make Health Systems Resilient.
(1mo)
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio launch ADME-One, a packaged ADME service for hit identification
(2mo)
AI Won't Replace Clinical Programmers. It Will Split Them Into Two Groups.
(2mo)
Novo Nordisk and OpenAI Team Up to Integrate AI from Discovery to Supply Chain
(3mo)
Life Biosciences Gets $80M as Cellular Rejuvenation Enters the Clinic
(3mo)
Jeito Closes €1B Fund, Europe's Largest Independent Biopharma Raise
(3mo)
Anthropic Pays $400M for an AI Biotech With Fewer Than Ten People
(3mo)
Epia Neuro Wants to Decode Brain's Movement Intentions After Stroke
(3mo)
Generare Raises €20M to Explore Uncharacterized Chemical Space from Microbial DNA
(3mo)
Drug Channels
Drug Channels News Roundup, Mid-July 2026: Biosimilar Launch Strategy, Part D Spending Trends, Rural 340B Hospitals, What Employers Can Do About 340B, and Drug Channel Villains
(8h)
Direct-to-Patient: Transforming the Manufacturer Access Model
(4d)
2025 Gross-to-Net Realities at Eight Top Drugmakers: The Net Pricing Drug Channel Emerges
(1w)
2025 Gross-to-Net Realities at Eight Top Drugmakers: The Net Pricing Drug Channel Emerges
(1w)
Direct-to-Consumer Shouldn't Always Mean Direct-To-Mail-Order: Why Fulfillment Choice Matters
(2w)
Direct-to-Consumer Shouldn't Always Mean Direct-To-Mail-Order: Why Fulfillment Choice Matters
(2w)
The 340B Program Hit $100 Billion in 2025: Has It Become Too Big to Reform?
(2w)
The 340B Program Hit $100 Billion in 2025: Has It Become Too Big to Reform?
(2w)
Medicare Embraces Site-Neutral Payments. Why Haven't Employers?
(2w)
Medicare Embraces Site-Neutral Payments. Why Haven't Employers?
(2w)
European Biotechnology Magazine
Pentixapharm raises €20.4M for Phase 3 diagnostic trial
(3h)
Chiesi retreats from Gossamer PAH programme after Phase 3 miss
(10h)
Fast-track trial approval: a way to jump the EU queue?
(1d)
argenx pays $2.2B for Forte’s early autoimmune promise
(1d)
BIO-Europe 2026
(1d)
CHMP backs Minoryx’s rare disease drug two years after rejection
(4d)
Sanofi drops eczema drug from $1.1B Kymab deal
(4d)
Iceland-based Synaptiq launches with Nobias’ rare disease drug
(4d)
Fresenius launches €200M healthcare venture fund
(5d)
Neurimmune turns future royalties into $425m pipeline cash
(5d)
Drug Hunter
BMS CAMK2 Inhibitor Patents Show a Continuing Paradigm Shift from Isoform Selectivity to Tissue Selectivity
(1h)
Module 5 Quiz
(1d)
zidebactam
(4d)
centanafadine
(5d)
thalidomide
(6d)
18F-florquinitau
(1w)
The NaV1.7 Disconnect: Pharmacologic Inhibition Does Not Recapitulate Genetic Loss
(1w)
Orum’s DACs Aim to Expand the Therapeutic Window of GSPT1 Degraders
(2w)
Emerging Strategies for GSPT1 Degradation
(2w)
nibrozetone
(2w)
Labiotech.EU
Mouse models and CRO selection critical to de-risking neurology drug development
(11h)
Six TIL therapy companies to watch out for
(1d)
Munich’s biotech hub: Inside one of Europe’s leading life sciences ecosystems
(4d)
This nonprofit is building the ecosystem to cure epidermolysis bullosa
(4d)
Is an HIV cure possible? The future of HIV therapy
(6d)
Roche’s new gene sequencer on the market: where do current players stand?
(1w)
Inside one of Europe’s most advanced biotech innovation hubs
(1w)
Guinea worm: Why disease eradication is so rare
(1w)
How BIO-Europe is expanding beyond dealmaking in 2026
(2w)
Race for approval: biotechs accelerate bipolar disorder therapies
(2w)
Bio IT World
Baylor College Serves as Sequencing Center, Immunai, Boehringer Ingelheim Multi-Project Collaboration, Spatial Biology
(14h)
The Most Expensive AI Mistake in Biotech Isn’t a Hallucination, It’s a Process Failure
(4d)
In Vivo CRISPR Therapy is One Step Closer to the Clinic
(5d)
Different Teams, Same Problem
(6d)
Winning Best of Show Again: A Reflection on MLADU, Research Data, and the Bio-IT World Community
(1w)
With AWS Help, UK Group Moves Toward Global AMR Intelligence Platform
(2w)
CFDE Promotes Collaboration to Build Creative and Practical Solutions to Data Challenges during the Bio-IT Hackathon
(2w)
How Sugar on Brain Cells May Be Driving Alzheimer’s and How a Common Joint Supplement May Be Making It Worse
(2w)
Signal Management Isn’t Broken; It Simply Belongs to a Previous Era
(3w)
Network Effects: John Quackenbush on How Networks Illuminate Biology Beyond Gene Expression
(3w)
GEN News
Nova Biomedical Acquires NanoCellect Assets to Expand Cell Line Development Portfolio
(2h)
Comprehensive Human Vagus Nerve Map Unveiled
(7h)
Parkinson’s Disease Medication Monitored with Fingertip Sweat Patch
(20h)
Solving the Mystery of Why Blocking and Stimulating a Brain Receptor Helps Weight Loss
(22h)
ALS Could Be Predicted Years Before Symptoms, Proteomics Study Finds
(23h)
StockWatch: Axiom CEO Explains Plans for Hong Kong IPO
(1d)
Colorectal Cancer Targeted with Mass-Produced iPSC-Derived Allogeneic T Cells
(4d)
Oral Antiviral Blocks Measles-Like Virus Transmission in Ferrets
(4d)
Single-Cell Atlas Simultaneously Maps 3D Genome Architecture and DNA Methylation
(4d)
Single-Cell Maps Reveal Genome Reorganization in Alzheimer’s Brain Cells
(4d)
Cure Today
Why I Chose a Treatment Break After Years of Living With Stage 4 Ovarian Cancer
(3d)
When the Scan Is Over but the Waiting Begins: Living With Lymphoma Scanxiety
(4d)
RASolute 302 and the Future of Pancreatic Cancer Treatment: Paul Oberstein, MD, on the KRAS Breakthrough
(4d)
Minimally Invasive Options in Rectal Cancer: TAMIS and Robotic Surgery
(5d)
Why I Don’t Want to Hear “You’ll Beat This” After a Metastatic Breast Cancer Diagnosis
(5d)
Diagnosed at 25 With Hodgkin's Lymphoma, She Says This Saved Her Life
(5d)
Cancer Care Leader Founds Program to Give Women Access to Cold Caps
(6d)
Choosing a Bra after a Mastectomy
(6d)
10 Things That Got Me Through Treatment ft. Edward Miskie
(7d)
The Healing Power of a Cancer Survivor Retreat During Scan Anxiety
(1w)
Contract Pharma
Why Spray Drying Is Gaining Attention as a Biologics Lifecycle Management Strategy
(2h)
ICON to Deploy Claude AI Across Clinical Trial Lifecycle
(5h)
ProBioGen Partners with VarmX to Advance Factor X Candidate
(6h)
Spruce Biosciences Welcomes Adrian Quartel as Chief Medical Officer
(1d)
AsymBio Breaks Ground on New Fengxian R&D Building
(1d)
Harbour BioMed and Sinopharm Will Establish R&D ‘Innovation Consortium’
(1d)
Kyverna, ElevateBio Ink Manufacturing Agreement for Miv-Cel Supply
(1d)
Big Pharma Invests in U.S. Manufacturing
(1d)
argenx to Acquire Forte Biosciences for $2.2 Billion
(1d)
Novogene Europe Adds Single-Cell Sequencing at Cambridge Omics Centre
(1d)
Pharma Times
OrbusNeich begins Japanese trial for drug‑coated balloon
(8h)
Nezglyal receives positive CHMP opinion supporting treatment access for boys with cALD
(9h)
Novogene Europe expands single‑cell sequencing capability in Cambridge
(1d)
MAD World Summit 2026
(1d)
GSK wins US approval for ROS1 lung cancer therapy
(5d)
Lundbeck secures FDA Fast Track for narcolepsy drug
(5d)
R1 Therapeutics begins global phase 2b trial of AP306 for hyperphosphatemia
(6d)
Mission Therapeutics divests MTX652 to Dimerix in deal worth up to $292 million
(6d)
Nouscom to present re‑treatment data in Lynch Syndrome at ESMO 2026
(1w)
ViiV Healthcare to unveil new HIV treatment data at AIDS 2026
(1w)
Medcity News
Why Specialized UM Delivers on Every NICU Outcome
(5h)
Spotting Alzheimer’s Years Earlier Through AI and Clinically Meaningful Insights
(5h)
Why Endeavor Health Refuses to Silo Its Value-Based Care Strategy
(19h)
Argenx’s $2B Forte Bio Acquisition Brings Autoimmune Playbook to Prevalent Disorders
(21h)
Prior Authorization Is Draining Revenue: Why Automation Has Become a Strategic Imperative
(1d)
How AI Inside Clinical Workflows Is Unlocking Patient Throughput
(1d)
AI Readiness Starts with Solving Healthcare’s Data Fragmentation Problem
(1d)
What Happens When Patients Trust AI Over Their Doctor?
(1d)
Crystalys Therapeutics Tacks On $130M for Pivotal Tests of Gout Drug
(1d)
Candid Health Snags $120M for AI RCM Platform
(2d)
Chemical & Engineering News
Business Watch: BioBTX moves on renewable aromatics; Scribe’s IPO is a hit
(38m)
Quiz: What causes sunscreen stains?
(2h)
The covalent drug arsenal gets a new warhead
(3h)
Chemistry in Pictures: Echoes of microplastics
(4h)
Can we stop AI from flooding scientific journals?
(5h)
While Bangladesh struggles to regulate pesticides, its farmers suffer
(1d)
Reaction rounds up atoms into unusual cyclic compounds
(1d)
Herman Frasch Fund opens for applications
(1d)
ACS names 2026 fellows
(1d)
Introducing rare earth MXenes
(1d)
The Pharma Letter
MapLight's schizophrenia candidate clears one bar but misses another
(3h)
ViiV's Dovato matches Gilead's Biktarvy in first head-to-head HIV trial
(4h)
MapLight's schizophrenia candidate clears one bar but misses another
(4h)
Ambrosia bolsters clinical team as it pushes oral obesity pill toward trials
(4h)
Claris Bio unveils development strategy
(4h)
GSK’s licensor Hansoh Pharma announces positive new Ris-Rez data
(4h)
Legend Biotech names interim CEO after Ying Huang steps down
(6h)
FDA panel raises doubts over Capricor’s deramiocel data ahead of DMD review
(7h)
Apnimed targets $150 million IPO ahead of potential sleep apnea drug launch
(7h)
China's biotech rise to face challenges from US policy responses
(9h)
Targeted Oncology
MCED Testing: Preparing for the Next Era of Cancer Risk Assessment
(2d)
Biomarkers Beyond High TMB or MMR-D May Be Needed for ICIs in Sarcomas
(2d)
Community Clinical Trials and the Lung Cancer Pipeline
(2d)
From Genetic Testing to Personalized Cancer Prevention
(3d)
Ethical Challenges Behind Genome Sequencing and Precision Medicine
(3d)
How Inherited BRCA Mutations Shape Breast Cancer's Genomic Behavior and Point Toward a New Treatment Paradigm
(3d)
Navigating CAR T Decision-Making in R/R DLBCL
(4d)
On-Body Injectors Point to At-Home Care, but Hurdles Remain in US
(4d)
Scaling Genetic Counseling in Community Oncology
(4d)
Changing ADC Choices for HR+/HER2–Breast Cancer
(4d)
MedWatch
Danish weight-loss company launches phase 2 trial for obesity and diabetes treatment
(6h)
Minerva Imaging enters into a new partnership with US company
(7h)
GSK beats consensus forecast in second quarter
(7h)
GSK beats consensus forecast in second quarter
(7h)
J&J reaches billion-dollar settlement with cancer plaintiffs
(8h)
Strategic changes lead Amgen to slash around 40 jobs
(9h)
Gubra sends asset to clinical trial and starts new front in the weight-loss race
(9h)
EIFO invests DKK 20m in biotech firm Quantumcell
(1d)
GE Healthcare CFO Jay Saccaro resigns
(1d)
Argenx buys Forte Biosciences for USD 2.2bn
(1d)
In The Pipeline
Preventing Misfolding by Preventing Folding
(1h)
Taking a Tip From Plants - For the Eyes?
(21h)
Clinical Failure Rates Over the Decades: Yikes
(4d)
The Assault On Science Funding Continues
(5d)
Thoughts on the "Netflix Analogy"
(5d)
Benchmarking the Benchmarks
(1w)
More Pancreatic Cancer Vaccine Progress - Treatment and Preventative
(1w)
More Condensate Secrets Revealed
(2w)
The Battle For Sickle Cell
(2w)
Tau In the Clinic, Again
(2w)
Pharmaphorum
GSK to quit Stevenage for new R&D site in Cambridge
(6h)
HIV resurgence looming as international aid declines
(7h)
Severino takes the helm at Sarepta after turbulent spell
(8h)
Scribe raises $155m in IPO, as Apnimed pitches for $150m
(9h)
Is J&J approaching the end of its talc litigation hangover?
(10h)
J&J's oral IL-23 drug backed for psoriasis in EU
(1d)
Chris McDonald replaces Vallance as UK science minister
(1d)
Outlook finally claims FDA approval for AMD drug
(1d)
Argenx pens $2.2bn deal to buy autoimmune biotech Forte
(1d)
Ultomiris fail mars AZ's strong Q2 results
(1d)
Drug Discovery Weekly
Wegovy pill could help patients lose 17% body weight
(1mo)
How AskBio is pioneering ‘transformative genetic therapies’ in Parkinson’s disease
(1mo)
Webinar: Learn how to accelerate the early stages of drug discovery
(1mo)
Therapy enables 89% survival rate in myeloma patients
(1mo)
Ulcerative colitis treatment shows best-in-class potential
(1mo)
UK patients to benefit from approval of weight loss tablet
(1mo)
Vertex presents new data on Casgevy in children
(1mo)
DDW Highlights: 16 June 2026
(1mo)
LXR inverse agonist shows promise in liver disease
(1mo)
Guide: One solution – from R&D, to QC
(1mo)
HIT Consultant
UC San Diego Engineers Develop Battery-Free Wearable Patch for Real-Time Parkinson’s Dosing
(21h)
Flourish Health Raises $26M to Expand In-Home High-Acuity Pediatric Mental Health
(21h)
Labcorp Launches Marker Genetic Health Panel on Labcorp OnDemand for 100+ Actionable Conditions
(1d)
HealthEx Unveils TEFCA-Accredited HealthEx Wallet & Partners with Sharecare to to Ground AskMD in Whole-Health Clinical Context
(1d)
Lapsi Health Partners with Redox to Integrate Keikku Clinical AI Platform Directly Into EHR Infrastructure
(1d)
Inner Logic Raises $11.5M to Build Simulation Infrastructure for Procedural Devices
(1d)
Medidata Launches Medidata Plus AI Layer to Standardize Clinical Trial Data and Workflows
(3d)
Wellumio Closes $9.75M to Commercialize Axana Portable Brain Imaging Device
(4d)
Cigna Healthcare Expands AI-Enabled Care Management to Reach 20% More Customers
(4d)
AdvancedMD Expands Waystar-Powered Revenue Cycle Offerings for Independent Practices
(4d)
Insights: Pink Sheet
US FDA Peptide Guidance Moves Could Affect GLP-1 Generic Development
(1h)
Spain’s No To Kisunla, Leqembi Funding Draws Backlash As UK’s NICE Reconsiders
(2h)
Canada’s Top Court Backs Janssen’s Invega Patent, Adopts ‘Balanced’ Position On Dosing IP
(3h)
Capricor’s Changing Trial Protocols Could Undermine Deramiocel At US FDA AdComm
(20h)
Beyond Operation TrialBlazer: Congress Sounds Ready To Act On IND Pathways
(22h)
New Cancer Clinical Trial Guidances Continue US FDA Push For Expanded Eligibility
(1d)
EMA Endorses New First-Line Roles For Enhertu, Trodelvy In Breast Cancer
(1d)
Roche’s Eye Implant Susvimo Set For EU Approval After Earlier Challenges
(1d)
EMA’s PRIME Scheme Sets First-Half Record, Eclipsing Its Weakest Full Year Intake
(1d)
Peptide Industry Reaps Six Wins From RFK Jr.-Remade FDA Panel
(3d)
BioXconomy
Veristat says clinical hold data key to FDA’s FIH trial network success
(5h)
Gene therapy and peptide combo restores heart health in mice
(3h)
Why patient services holds the key to accurate GTN forecasting
(3h)
EMA selects TrialAssure to anonymize public clinical trial documents
(4h)
Sanofi and Servier execs talk oncology: Pitches, Europe's position, and China's advantage
(5h)
New finance chiefs named
(6h)
Argenx gets the immunology Forte with $2.2bn acquisition
(10h)
The connected CDMO: How oversharing enables true partnership in biologics
(1d)
Scribe rips the script with upsized $128.7m IPO
(1d)
SEC's semiannual reporting proposal debate continues
(4d)
BioCentury
CEOs departing Legend, Sarepta
(19h)
Argenx M&A, AI giants in biopharma, catalyst scorecard — a BioCentury podcast
(19h)
SPAC, reverse merger take Oak Hill, Scancell to NASDAQ
(20h)
Maplight falls as once-daily arm of Cobenfy rival misses in schizophrenia
(20h)
Argenx enters biotech buyer class with $2.2B Forte takeout
(21h)
Song among trio of new partners at Venrock
(3d)
Hub 101: Taiwan biotech looks to level up
(3d)
EMA’s CHMP backs two orphan drugs, rebuffs FDA-approved NPC therapy
(3d)
Scribe extends run of strong biotech IPO debuts: Public Equity Report
(4d)
Mapping AI giants’ bets across the biopharma tech stack
(4d)
SCRIP
Gossamer’s Seralutinib NDA Plans Intact After FDA Clears Filing Path
(4h)
GSK Cuts Costs With Phase III Starts Set To Double
(4h)
Sarepta Taps Outsider CEO As Exon-Skippers Face Key Test
(4h)
As Tech Stocks Tumble, AstraZeneca Reins In AI Spending
(4h)
Stock Watch: Why Novartis Stock Rose On Results Half As Good As J&J’s
(5h)
Late To The Party: Can Cipla’s Generic Advair Catch Up In The US Market?
(6h)
CSPC’s Novel Antidepressant Hits Mark In First-Line China Phase III Trial
(10h)
Chugai Fortifies Investment Function Amid Successful H1
(11h)
Finance Watch: Scribe Launches IPO, Oak Hill Going Public Via SPAC Merger
(22h)
MapLight’s ZEPHYR Trial Hits Endpoints In Schizophrenia, But Investors Want To See More
(22h)